2018 Q3 Form 10-Q Financial Statement
#000114420418042241 Filed on August 07, 2018
Income Statement
| Concept | 2018 Q3 | 2018 Q2 | 2017 Q2 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Cost Of Revenue | |||
| YoY Change | |||
| Gross Profit | |||
| YoY Change | |||
| Gross Profit Margin | |||
| Selling, General & Admin | $7.110M | $6.830M | $3.930M |
| YoY Change | 54.9% | 73.79% | -45.87% |
| % of Gross Profit | |||
| Research & Development | $27.95M | $24.55M | $18.65M |
| YoY Change | 67.56% | 31.66% | 317.81% |
| % of Gross Profit | |||
| Depreciation & Amortization | $250.0K | $220.0K | $240.0K |
| YoY Change | 0.0% | -8.33% | -11.11% |
| % of Gross Profit | |||
| Operating Expenses | $35.06M | $31.38M | $23.58M |
| YoY Change | 56.92% | 33.06% | 101.08% |
| Operating Profit | -$35.06M | -$31.38M | -$23.58M |
| YoY Change | 56.92% | 33.06% | 101.08% |
| Interest Expense | $1.230M | $720.0K | $200.0K |
| YoY Change | 547.37% | 260.0% | 25.0% |
| % of Operating Profit | |||
| Other Income/Expense, Net | |||
| YoY Change | |||
| Pretax Income | -$33.83M | -$30.66M | -$23.38M |
| YoY Change | 52.73% | 31.14% | 102.25% |
| Income Tax | |||
| % Of Pretax Income | |||
| Net Earnings | -$33.83M | -$30.66M | -$23.38M |
| YoY Change | 52.74% | 31.15% | 102.17% |
| Net Earnings / Revenue | |||
| Basic Earnings Per Share | |||
| Diluted Earnings Per Share | -$355.8K | -$339.8K | -$374.3K |
| COMMON SHARES | |||
| Basic Shares Outstanding | 95.59M shares | 62.35M shares | |
| Diluted Shares Outstanding |
Balance Sheet
| Concept | 2018 Q3 | 2018 Q2 | 2017 Q2 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $260.0M | $276.1M | $129.0M |
| YoY Change | 59.12% | 114.03% | -32.67% |
| Cash & Equivalents | $80.74M | $246.0M | $114.3M |
| Short-Term Investments | $179.3M | $30.10M | $14.70M |
| Other Short-Term Assets | $5.900M | $3.700M | $6.400M |
| YoY Change | -26.25% | -42.19% | 700.0% |
| Inventory | |||
| Prepaid Expenses | |||
| Receivables | |||
| Other Receivables | |||
| Total Short-Term Assets | $265.9M | $279.8M | $135.4M |
| YoY Change | 55.11% | 106.58% | -29.59% |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | $2.640M | $2.706M | $2.578M |
| YoY Change | 1.54% | 4.97% | 116.28% |
| Goodwill | |||
| YoY Change | |||
| Intangibles | |||
| YoY Change | |||
| Long-Term Investments | |||
| YoY Change | |||
| Other Assets | $2.331M | $2.264M | |
| YoY Change | |||
| Total Long-Term Assets | $4.971M | $4.970M | $2.578M |
| YoY Change | 91.19% | 92.79% | 116.28% |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $265.9M | $279.8M | $135.4M |
| Total Long-Term Assets | $4.971M | $4.970M | $2.578M |
| Total Assets | $270.8M | $284.8M | $138.0M |
| YoY Change | 55.65% | 106.32% | -28.69% |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $6.014M | $5.196M | $3.695M |
| YoY Change | 107.38% | 40.62% | 409.66% |
| Accrued Expenses | $10.66M | $8.986M | $5.165M |
| YoY Change | 90.36% | 73.98% | 33.08% |
| Deferred Revenue | |||
| YoY Change | |||
| Short-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Long-Term Debt Due | |||
| YoY Change | |||
| Total Short-Term Liabilities | $16.67M | $14.18M | $8.860M |
| YoY Change | 96.16% | 60.07% | 92.36% |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Other Long-Term Liabilities | |||
| YoY Change | |||
| Total Long-Term Liabilities | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $16.67M | $14.18M | $8.860M |
| Total Long-Term Liabilities | $0.00 | $0.00 | $0.00 |
| Total Liabilities | $16.70M | $14.20M | $8.900M |
| YoY Change | 96.47% | 59.55% | 93.48% |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | -$340.2M | -$306.4M | -$201.2M |
| YoY Change | 52.28% | 64.0% | |
| Common Stock | $4.000K | $4.000K | $3.000K |
| YoY Change | 33.33% | 0.0% | |
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | |||
| YoY Change | |||
| Treasury Stock Shares | |||
| Shareholders Equity | $254.2M | $270.6M | $129.2M |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $270.8M | $284.8M | $138.0M |
| YoY Change | 55.65% | 106.32% | -28.69% |
Cashflow Statement
| Concept | 2018 Q3 | 2018 Q2 | 2017 Q2 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | -$33.83M | -$30.66M | -$23.38M |
| YoY Change | 52.74% | 31.15% | 102.17% |
| Depreciation, Depletion And Amortization | $250.0K | $220.0K | $240.0K |
| YoY Change | 0.0% | -8.33% | -11.11% |
| Cash From Operating Activities | -$27.93M | -$23.92M | -$17.50M |
| YoY Change | 30.21% | 36.69% | 366.67% |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | -$460.0K | -$420.0K | -$20.00K |
| YoY Change | 70.37% | 2000.0% | -66.67% |
| Acquisitions | |||
| YoY Change | |||
| Other Investing Activities | -$148.9M | -$30.08M | $25.36M |
| YoY Change | -1109.56% | -218.61% | -345.26% |
| Cash From Investing Activities | -$149.4M | -$30.50M | $25.33M |
| YoY Change | -1130.92% | -220.41% | -343.56% |
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | |||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | |||
| YoY Change | |||
| Debt Paid & Issued, Net | |||
| YoY Change | |||
| Cash From Financing Activities | 12.02M | 3.360M | -650.0K |
| YoY Change | -78.56% | -616.92% | -100.68% |
| NET CHANGE | |||
| Cash From Operating Activities | -27.93M | -23.92M | -17.50M |
| Cash From Investing Activities | -149.4M | -30.50M | 25.33M |
| Cash From Financing Activities | 12.02M | 3.360M | -650.0K |
| Net Change In Cash | -165.3M | -51.06M | 7.180M |
| YoY Change | -436.64% | -811.14% | -91.25% |
| FREE CASH FLOW | |||
| Cash From Operating Activities | -$27.93M | -$23.92M | -$17.50M |
| Capital Expenditures | -$460.0K | -$420.0K | -$20.00K |
| Free Cash Flow | -$27.47M | -$23.50M | -$17.48M |
| YoY Change | 29.7% | 34.44% | 373.71% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| us-gaap |
Loss Contingency Disclosures
LossContingencyDisclosures
|
<div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;"><div style="font-family: "times new roman", serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-decoration:underline;display:inline;"><div style="font-weight:bold;display:inline;">NOTE 8. LEGAL PROCEEDINGS</div></div></div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: -0.5in; margin-left: 0.5in; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.50in;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-decoration:underline;display:inline;">Class Action Lawsuit and Derivative Lawsuits</div>. On April 10, 2017, the SEC announced settlements with us and with other public companies and unrelated parties in the <div style="font-style:italic;display:inline;">In the Matter of Certain Stock Promotion </div>investigation. Our settlement with the SEC is consistent with our previous disclosures (including in our Annual Report on Form 10-K that we filed with the SEC on March 9, 2017). On April 14, 2017, a purported shareholder filed a complaint seeking class action status in the United States District Court, Northern District of California for violations of the federal securities laws (<div style="font-style:italic;display:inline;">Leonard DeSilvio v. Lion Biotechnologies, Inc., et al., </div>case no. 3:17-cv-2086) against our company and three of our former officers and directors. On April 19, 2017, a second class action complaint <div style="font-style:italic;display:inline;">(Amra Kuc vs. Lion Biotechnologies, Inc., et al., </div> case no. 3:17-cv-2188) was filed in the same court. Both complaints allege, among other things, that the defendants violated the federal securities laws by making materially false and misleading statements, or by failing to make certain disclosures, regarding the actions taken by Manish Singh, our former CEO, and our former investor relations firm that were the subject of the <div style="font-style:italic;display:inline;">In the Matter of Certain Stock Promotions </div>investigation. On July 20, 2017, the plaintiff in the <div style="font-style:italic;display:inline;">Kuc </div>case filed a notice to voluntarily dismiss that case. The court entered an order dismissing the <div style="font-style:italic;display:inline;">Kuc </div>complaint on July 21, 2017. On July 26, 2017, the court appointed a movant as lead plaintiff. On September 8, 2017, the lead plaintiff filed an amended complaint (<div style="font-style:italic;display:inline;">Jay Rabkin v. Lion Biotechnologies, Inc., et al., </div>case no. 3:17-cv-2086) seeking class action status that alleges, among other things, that the defendants violated federal securities laws by making materially false and misleading statements, or by failing to make certain disclosures, regarding the actions taken by Manish Singh and our former investor relations firm that were the subject of the <div style="font-style:italic;display:inline;">In the Matter of Certain Stock Promotions </div>SEC investigation. On February 5, 2018, the court entered an order dismissing two of plaintiff’s six claims.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.50in;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On December 15, 2017, a purported stockholder derivative complaint was filed by plaintiff Kevin Fong on behalf of the Company, against the Company, as nominal defendant, and certain of the Company’s current and former officers and directors, and others, as defendants, in the U.S. District Court for the District of Delaware (case no. 1:17-cv-1806). The complaint alleges breaches of fiduciary duties, unjust enrichment, and violations of Section 14(a) of the Securities Exchange Act of 1934 and Rule 14a-9 promulgated thereunder arising from the SEC’s investigation in the <div style="font-style:italic;display:inline;">In the Matter of Certain Stock Promotions </div>investigation and our April 10, 2017 settlement thereof, and seeks unspecified damages on behalf of our company and injunctive relief.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.50in;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March 28, 2018, a purported stockholder derivative complaint was filed by plaintiff Nazeer Khaleeluddin on behalf of the Company, against the Company, as nominal defendant, and certain of the Company’s current and former officers and directors, and others, as defendants, in the U.S. District Court for the District of Delaware (case no. 1:18-cv-00469). The complaint alleges, among other things, violations of securities law, breach of fiduciary duty, aiding and abetting, waste of corporate assets, and unjust enrichment. The complaint is based on claims arising from the SEC’s investigation in the <div style="font-style:italic;display:inline;">In the Matter of Certain Stock Promotions</div> investigation and the Company’s April 10, 2017 settlement thereof, and seeks unspecified damages on behalf of our company and injunctive relief. On May 1, 2018, the court consolidated this case with the aforementioned purported stockholder derivative case filed by plaintiff Kevin Fong.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.50in;"><div style="font-family: "times new roman", serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We intend to vigorously defend against the foregoing complaints. Based on the very early stage of the litigation, it is not possible to estimate the amount or range of possible loss that might result from an adverse judgment or a settlement of these matters.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; background: none;"><div style="white-space: pre-wrap; font-family: "times new roman", serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.50in;"><div style="font-family: "times new roman", serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-decoration:underline;display:inline;">Solomon Capital, LLC.</div> On April 8, 2016, a lawsuit titled <div style="font-style:italic;display:inline;">Solomon Capital, LLC, Solomon Capital 401(K) Trust, Solomon Sharbat and Shelhav Raff v. Lion Biotechnologies, Inc.</div></div><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> was filed by Solomon Capital, LLC, Solomon Capital 401(k) Trust, Solomon Sharbat and Shelhav Raff against the Company in the Supreme Court of the State of New York, County of New York (index no. 651881/2016). The plaintiffs allege that, between June and November 2012 they provided to the Company $0.1 million and that they advanced and paid on our behalf an additional $0.2 million. The complaint further alleges that the Company agreed to (i) provide them with promissory notes totaling $0.2 million, plus interest, (ii) issue a total of 111,425 shares to the plaintiffs (before the 1-for-100 reverse split of our common stock effected in March 2013), and (iii) allow the plaintiffs to convert the foregoing funds into our securities in the next transaction. The plaintiffs allege that they should have been able to convert their advances and payments into shares of the Company’s common stock in the restructuring that was affected in May 2013. Based on the foregoing, the plaintiffs allege causes for breach of contract and unjust enrichment and demand judgment against the Company in an unspecified amount exceeding $1.5 million, plus interest and attorneys’ fees.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.50in;"><div style="font-family: "times new roman", serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On June 3, 2016, the Company filed an answer and counterclaims in the lawsuit. In its counterclaims, the Company alleges that the plaintiffs misrepresented their qualifications to assist it in fundraising and that they failed to disclose that they were under investigation for securities laws violations. The Company is seeking damages in an amount exceeding $0.5 million and an order rescinding any and all agreements that the plaintiffs contend entitled them to obtain stock in the Company.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.50in;"><div style="font-family: "times new roman", serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On April 19, 2017, the court granted plaintiffs’ counsel’s motion to withdraw from the case. On May 25, 2017, plaintiffs filed a notice that they had hired new counsel. On June 7, 2017, the judge presiding over the case recused herself because of a conflict of interest arising from her relationship with plaintiffs’ new attorneys, and the case was subsequently assigned to a new judge. On April 20, 2018, the court held a hearing regarding plaintiff’s motion to dismiss certain counterclaims by the Company.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.50in;"><div style="font-family: "times new roman", serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company intends to vigorously defend the complaint and pursue its counterclaims.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; background: none;"><div style="white-space: pre-wrap; font-family: "times new roman", serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.50in;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-decoration:underline;display:inline;">Litigation Involving Dr. Steven Fischkoff</div>. On June 13, 2017, in an action titled <div style="font-style:italic;display:inline;">Steven Fischkoff v. Lion Biotechnologies, Inc. and Maria Fardis</div>, Dr. Steven Fischkoff, our former Vice President and Chief Medical Officer, filed a lawsuit against the Company and Dr. Fardis in the Supreme Court of the State of New York County of New York. Dr. Fischkoff was dismissed by the Company on March 28, 2017. Dr. Fischkoff was terminated “for cause” as that term is defined in his employment agreement. In his complaint, Dr. Fischkoff alleges breaches of his employment agreement and violation of New York Labor Law for failure to pay monies purportedly owed to him, and seeks to recover amounts including severance pay and retention bonus (totaling $300,000), a prorated incentive bonus, and amounts relating to unvested options to 150,000 shares of our common stock, together with prejudgment interest, costs, expenses and attorneys’ fees. On July 5, 2017, the Company filed a removal petition and removed the lawsuit to the United States District Court for the Southern District of New York, where the case has been assigned case no. 1:17-cv-05041. On July 14, 2017, the Company filed a partial answer and counterclaims against Dr. Fischkoff, denying his allegations, and alleging breach of contract and related claims, breach of fiduciary duty, and state and federal trade secret misappropriation and related claims, and sought a temporary restraining order and preliminary injunction against Dr. Fischkoff. On July 18, 2017, the court issued a temporary restraining order against Dr. Fischkoff requiring him to return Company materials, prohibiting him from disclosing or using Company materials, and granting expedited discovery. On June 25, 2018, pursuant to a stipulation between the parties, the court entered a permanent injunction prohibiting Dr. Fischkoff from disclosing, possessing, or using any of the Company’s proprietary materials or trade secrets. On July 5, 2018, the court entered an order dismissing two of Dr. Fischkoff’s claims against the Company and Dr. Fardis. On July 27, 2018, the Company filed a motion seeking to add four additional counterclaims against Dr. Fischkoff, including counterclaims relating to conversion, theft, and computer fraud and abuse. The court has not yet rendered a decision on this motion.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.50in;"><div style="font-family: "times new roman", serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We intend to vigorously defend against Dr. Fischkoff’s lawsuit and pursue the Company’s counterclaims. Based on the very early stage of the litigation, it is not possible to estimate the amount or range of (i) a possible loss that might result from an adverse judgment or settlement of this action, or (ii) the potential recovery that might result from a favorable judgment or a settlement of this action.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; background: none;"><div style="white-space: pre-wrap; font-family: "times new roman", serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.50in;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-decoration:underline;display:inline;">Other Matters.</div> During the second quarter of 2016, warrants representing 128,500 shares were exercised. The 128,500 shares of common stock had previously been registered for re-sale. However, we believe that these 128,500 warrant shares were sold by the holders in open market transactions in May 2016 at a time when the registration statement was ineffective. Accordingly, those sales were not made in accordance with Sections 5 and 10(a)(3) of the Securities Act, and the purchasers of those shares may have rescission rights (if they still own the shares) or claims for damages (if they no longer own the shares). The amount of any such liability is uncertain and as such, an accrual for any potential loss has not been made. The Company believes that any claims brought against it would not result in a material impact to the Company’s financial position or results of operations. The Company has not accrued a loss for a potential claim associated with this matter as it is unable to estimate any at this time.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.50in;"><div style="font-family: "times new roman", serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company may be involved, from time to time, in legal proceedings and claims arising in the ordinary course of its business. Such matters are subject to many uncertainties and outcomes are not predictable with assurance. The Company accrues amounts, to the extent they can be reasonably estimated, that it believes are adequate to address any liabilities related to legal proceedings and other loss contingencies that the Company believes will result in a probable loss. While there can be no assurances as to the ultimate outcome of any legal proceeding or other loss contingency involving the Company, management does not believe any pending matter will be resolved in a manner that would have a material adverse effect on the Company’s financial position, results of operations or cash flows.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> | ||
| us-gaap |
Revenues
Revenues
|
0 | USD | |
| us-gaap |
Revenues
Revenues
|
0 | USD | |
| CY2018Q2 | us-gaap |
Revenues
Revenues
|
0 | USD |
| CY2017Q2 | us-gaap |
Revenues
Revenues
|
0 | USD |
| CY2018Q2 | us-gaap |
Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
|
2613000 | USD |
| CY2017Q4 | us-gaap |
Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
|
2613000 | USD |
| CY2018Q2 | us-gaap |
Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
|
501000 | USD |
| us-gaap |
Net Income Loss
NetIncomeLoss
|
-44061000 | USD | |
| CY2018Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-30660000 | USD |
| CY2017Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-23377000 | USD |
| CY2018Q2 | us-gaap |
Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
|
707000 | USD |
| CY2018Q2 | iova |
Legal And Related Services Current
LegalAndRelatedServicesCurrent
|
552000 | USD |
| CY2017Q4 | iova |
Legal And Related Services Current
LegalAndRelatedServicesCurrent
|
935000 | USD |
| CY2018Q2 | us-gaap |
Operating Expenses
OperatingExpenses
|
31378000 | USD |
| us-gaap |
Use Of Estimates
UseOfEstimates
|
<div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;"><div style="font-family: "times new roman", serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;">Use of Estimates</div></div></div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.50in;"><div style="font-family: "times new roman", serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include valuation of short-term investments, the useful lives of property and equipment, accounting for potential liabilities, the valuation allowance associated with the Company’s deferred tax assets, and the assumptions made in valuing stock instruments issued for services.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> | ||
| CY2018Q2 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
24551000 | USD |
| CY2017Q2 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
18647000 | USD |
| us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
44463000 | USD | |
| us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
34240000 | USD | |
| CY2018Q2 | iova |
Clinical Related Expenses Current
ClinicalRelatedExpensesCurrent
|
3920000 | USD |
| CY2017Q4 | iova |
Clinical Related Expenses Current
ClinicalRelatedExpensesCurrent
|
3310000 | USD |
| CY2018Q2 | us-gaap |
Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
|
495000 | USD |
| CY2018Q2 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
-3000 | USD |
| CY2017Q2 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
-2000 | USD |
| us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
-3000 | USD | |
| us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
-29000 | USD | |
| dei |
Document Type
DocumentType
|
10-Q | ||
| dei |
Amendment Flag
AmendmentFlag
|
false | ||
| us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-57178000 | USD | |
| us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-44090000 | USD | |
| CY2018Q2 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-30663000 | USD |
| CY2017Q2 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-23379000 | USD |
| us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
453000 | USD | |
| us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
464000 | USD | |
| CY2018Q2 | us-gaap |
Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
|
169000 | USD |
| CY2018Q2 | iova |
Manufacturing Related Expenses Current
ManufacturingRelatedExpensesCurrent
|
1150000 | USD |
| CY2017Q4 | iova |
Manufacturing Related Expenses Current
ManufacturingRelatedExpensesCurrent
|
876000 | USD |
| us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
13792000 | USD | |
| us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
10224000 | USD | |
| CY2018Q2 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
6827000 | USD |
| CY2017Q2 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
4934000 | USD |
| CY2018Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
246017000 | USD |
| CY2017Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
145373000 | USD |
| CY2017Q2 | us-gaap |
Operating Expenses
OperatingExpenses
|
23581000 | USD |
| us-gaap |
Operating Expenses
OperatingExpenses
|
58255000 | USD | |
| us-gaap |
Operating Expenses
OperatingExpenses
|
44464000 | USD | |
| us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
|
9326000 | USD | |
| us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
|
6589000 | USD | |
| CY2018Q2 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
|
5222000 | USD |
| CY2017Q2 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
|
3293000 | USD |
| CY2018Q2 | us-gaap |
Accrued Rent Current
AccruedRentCurrent
|
363000 | USD |
| CY2017Q4 | us-gaap |
Accrued Rent Current
AccruedRentCurrent
|
430000 | USD |
| CY2018Q2 | us-gaap |
Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
|
1872000 | USD |
| us-gaap |
Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
|
-9000 | USD | |
| us-gaap |
Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
|
0 | USD | |
| dei |
Document Period End Date
DocumentPeriodEndDate
|
2018-06-30 | ||
| CY2018Q2 | us-gaap |
Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
|
30082000 | USD |
| CY2017Q4 | us-gaap |
Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
|
0 | USD |
| dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2018 | ||
| us-gaap |
Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
|
-1000 | USD | |
| us-gaap |
Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
|
37000 | USD | |
| CY2018Q2 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
388000 | USD |
| CY2017Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
496000 | USD |
| us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-58255000 | USD | |
| us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-44464000 | USD | |
| CY2018Q2 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-31378000 | USD |
| CY2017Q2 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-23581000 | USD |
| CY2018Q2 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
3682000 | USD |
| CY2017Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
3917000 | USD |
| CY2018Q2 | us-gaap |
Assets Current
AssetsCurrent
|
279781000 | USD |
| CY2017Q4 | us-gaap |
Assets Current
AssetsCurrent
|
149290000 | USD |
| CY2018Q2 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.000041666 | |
| CY2017Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.000041666 | |
| CY2018Q2 | us-gaap |
Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
|
79933000 | USD |
| CY2017Q4 | us-gaap |
Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
|
91281000 | USD |
| CY2018Q2 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
8986000 | USD |
| CY2017Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
8660000 | USD |
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
9326000 | USD | |
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
6589000 | USD | |
| dei |
Entity Registrant Name
EntityRegistrantName
|
IOVANCE BIOTHERAPEUTICS, INC. | ||
| CY2018Q2 | iova |
Payments For Legal Services
PaymentsForLegalServices
|
200000 | USD |
| iova |
Payments For Legal Services
PaymentsForLegalServices
|
200000 | USD | |
| dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
Q2 | ||
| CY2018Q2 | us-gaap |
Due To Related Parties Current
DueToRelatedPartiesCurrent
|
300000 | USD |
| CY2017Q2 | us-gaap |
Due To Related Parties Current
DueToRelatedPartiesCurrent
|
400000 | USD |
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0 | pure | |
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0 | pure | |
| CY2018Q2 | us-gaap |
Held To Maturity Securities Current
HeldToMaturitySecuritiesCurrent
|
110016000 | USD |
| CY2017Q4 | us-gaap |
Held To Maturity Securities Current
HeldToMaturitySecuritiesCurrent
|
91281000 | USD |
| CY2018Q2 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
718000 | USD |
| CY2017Q2 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
204000 | USD |
| us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
1080000 | USD | |
| us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
403000 | USD | |
| CY2017Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
150000000 | shares |
| CY2018Q2 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
150000000 | shares |
| CY2018Q2 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
2706000 | USD |
| CY2017Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
2450000 | USD |
| CY2018Q2 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
2264000 | USD |
| CY2017Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
3633000 | USD |
| CY2018Q2 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
92741672 | shares |
| CY2017Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
73164914 | shares |
| us-gaap |
Net Income Loss
NetIncomeLoss
|
-57175000 | USD | |
| us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
17798880 | shares | |
| us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
22245886 | shares | |
| us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-1604000 | USD | |
| us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
3375000 | USD | |
| dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001425205 | ||
| iova |
Trading Securities Accretion
TradingSecuritiesAccretion
|
2000 | USD | |
| dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | ||
| us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
3686000 | USD | |
| us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
2987000 | USD | |
| CY2017Q2 | us-gaap |
Lease And Rental Expense
LeaseAndRentalExpense
|
200000 | USD |
| us-gaap |
Lease And Rental Expense
LeaseAndRentalExpense
|
500000 | USD | |
| CY2018Q2 | us-gaap |
Lease And Rental Expense
LeaseAndRentalExpense
|
7000 | USD |
| CY2018Q2 | us-gaap |
Lease And Rental Expense
LeaseAndRentalExpense
|
200000 | USD |
| us-gaap |
Lease And Rental Expense
LeaseAndRentalExpense
|
500000 | USD | |
| CY2018Q2 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.34 | |
| CY2017Q2 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.37 | |
| us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.65 | ||
| us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.71 | ||
| CY2018Q2 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
92741672 | shares |
| CY2017Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
73164914 | shares |
| CY2018Q2 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
5196000 | USD |
| CY2017Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
1232000 | USD |
| us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
87310 | shares | |
| us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
62371 | shares | |
| CY2018Q2 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
90236 | shares |
| CY2017Q2 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
62457 | shares |
| us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
326000 | USD | |
| us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
1060000 | USD | |
| dei |
Entity Filer Category
EntityFilerCategory
|
Accelerated Filer | ||
| CY2018Q2 | us-gaap |
Held To Maturity Securities Accumulated Unrecognized Holding Gain
HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
|
0 | USD |
| CY2017Q4 | us-gaap |
Held To Maturity Securities Accumulated Unrecognized Holding Gain
HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
|
0 | USD |
| dei |
Trading Symbol
TradingSymbol
|
IOVA | ||
| us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-41772000 | USD | |
| us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-36299000 | USD | |
| CY2017Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Terms Of Award
ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward
|
The granted stock options vest in 12 quarterly installments (with 1/12th of the option shares having vested on the date of grant). | |
| CY2018Q2 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
14182000 | USD |
| CY2018Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
270569000 | USD |
| CY2017Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
145481000 | USD |
| us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
172940000 | USD | |
| us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
-265000 | USD | |
| us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
100644000 | USD | |
| us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
7568000 | USD | |
| CY2016Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
106717000 | USD |
| CY2017Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
9892000 | USD |
| CY2018Q3 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
95592169 | shares |
| us-gaap |
Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
|
0 | USD | |
| us-gaap |
Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
|
44955000 | USD | |
| CY2018Q2 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
USD | |
| CY2017Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
USD | |
| us-gaap |
Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
|
30084000 | USD | |
| us-gaap |
Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
|
0 | USD | |
| us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
440000 | USD | |
| us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
823000 | USD | |
| CY2018Q2 | us-gaap |
Common Stock Value
CommonStockValue
|
4000 | USD |
| CY2017Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
3000 | USD |
| us-gaap |
Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
|
122000 | USD | |
| us-gaap |
Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
|
1161000 | USD | |
| CY2018Q2 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
-3000 | USD |
| CY2017Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
0 | USD |
| us-gaap |
Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
|
4141000 | USD | |
| us-gaap |
Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
|
250000 | USD | |
| CY2018Q2 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
576917000 | USD |
| CY2017Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
394651000 | USD |
| CY2018Q2 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-306355000 | USD |
| CY2017Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-249180000 | USD |
| us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
6828000 | USD | |
| us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
646000 | USD | |
| CY2016Q2 | us-gaap |
Loss Contingency Damages Sought Value
LossContingencyDamagesSoughtValue
|
500000 | USD |
| us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
162093000 | USD | |
| us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
0 | USD | |
| iova |
Common Stock Registered For Resale
CommonStockRegisteredForResale
|
128500 | shares | |
| CY2017Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
114285000 | USD |
| iova |
Number Of Share Options Or Share Units Exercised During Current Period
NumberOfShareOptionsOrShareUnitsExercisedDuringCurrentPeriod
|
128500 | shares | |
| iova |
Unrealized Gain Loss On Shortterm Investments
UnrealizedGainLossOnShorttermInvestments
|
-3000 | USD | |
| iova |
Unrealized Gain Loss On Shortterm Investments
UnrealizedGainLossOnShorttermInvestments
|
-29000 | USD | |
| iova |
Leasehold Improvements Paid By Landlord
LeaseholdImprovementsPaidByLandlord
|
-278000 | USD | |
| iova |
Leasehold Improvements Paid By Landlord
LeaseholdImprovementsPaidByLandlord
|
-155000 | USD | |
| CY2018Q2 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
|
38100000 | USD |
| us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
|
P2Y2M8D | ||
| CY2018Q1 | us-gaap |
Shares Issued Price Per Share
SharesIssuedPricePerShare
|
11.50 | |
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
4600000 | USD | |
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
200000 | USD | |
| CY2018Q2 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
5200000 | USD |
| CY2017Q2 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
3000000 | USD |
| CY2016Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
|
137500 | shares |
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
15.26 | ||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
6.83 | ||
| CY2018Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
|
91665 | shares |
| CY2018Q2 | us-gaap |
Assets
Assets
|
284751000 | USD |
| iova |
Reversal Of Prior Period Expense
ReversalOfPriorPeriodExpense
|
400000 | USD | |
| CY2017Q4 | us-gaap |
Held To Maturity Securities Accumulated Unrecognized Holding Loss
HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
|
0 | USD |
| CY2018Q2 | us-gaap |
Held To Maturity Securities Accumulated Unrecognized Holding Loss
HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
|
3000 | USD |
| CY2017Q4 | us-gaap |
Investment Owned At Fair Value
InvestmentOwnedAtFairValue
|
91281000 | USD |
| CY2018Q2 | us-gaap |
Investment Owned At Fair Value
InvestmentOwnedAtFairValue
|
110015000 | USD |
| us-gaap |
Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
|
1000 | USD | |
| us-gaap |
Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
|
0 | USD | |
| us-gaap |
Conversion Of Stock Shares Converted1
ConversionOfStockSharesConverted1
|
1250549 | shares | |
| CY2018Q2 | us-gaap |
Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
|
30082000 | USD |
| CY2017Q4 | us-gaap |
Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
|
0 | USD |
| iova |
Proceeds From Stock Options And Warrants Exercised
ProceedsFromStockOptionsAndWarrantsExercised
|
11000000 | USD | |
| CY2017Q4 | us-gaap |
Assets
Assets
|
155373000 | USD |
| CY2018Q2 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
284751000 | USD |
| CY2017Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
155373000 | USD |
| CY2018Q2 | us-gaap |
Assets Fair Value Disclosure
AssetsFairValueDisclosure
|
30082000 | USD |
| us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-30524000 | USD | |
| us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
44132000 | USD | |
| us-gaap |
Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
|
<div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;"><div style="font-family: "times new roman", serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;">Reclassifications</div></div></div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; background: none;"><div style="white-space: pre-wrap; font-family: "times new roman", serif; font-size: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.50in;"><div style="font-family: "times new roman", serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certain amounts within the statements of operations for the prior periods have been reclassified to conform with the current period presentation. These reclassifications had no impact on the Company's previously reported financial position or cash flows for any of the periods presented.</div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.50in;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-indent: 0.5in;;display:inline;"> </div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> |
